Anthracycline Chemo Regimen Seems Better Than Regimen Without Anthracycline for Early-Stage, HER2-Negative, High-Risk Disease
Early results suggest that an anthracycline chemotherapy regimen is better than a regimen without an anthracycline for early-stage, HER2-negative disease with a high risk of recurrence.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.